## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.98 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($953.73)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Eli Lilly and Company (LLY): A Bull Case Theory**
- Source: Finviz | 20251204T114400 | Bullish | Relevance: 100%
- This article summarizes a bullish thesis on Eli Lilly and Company (LLY), highlighting its strong position in the cardiometabolic health segment with drugs like Mounjaro and Zepbound. Despite an 18% YTD stock drop, the company presents a compelling BUY opportunity due to its leadership in addressing major health issues like obesity and Alzheimer's, strong operational profitability, and significant R&D capabilities. A DCF analysis suggests a three-year price target of $1,317, supported by industry tailwinds and pipeline strength.

**2. 1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year**
- Source: Finviz | 20251204T080925 | Bullish | Relevance: 100%
- Eli Lilly stock has seen significant growth, driven by its blockbuster weight loss drug portfolio, Mounjaro and Zepbound, which dominate the market alongside Novo Nordisk. The company is preparing for a new growth driver, orforglipron, a potential oral weight loss pill, and is investing heavily in manufacturing capacity in anticipation of its 2026 approval. This new oral option could broaden Lilly's addressable market and supercharge revenue, making it an opportune time to invest in the stock.

**3. Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca**
- Source: CoinCentral | 20251203T220804 | Somewhat-Bullish | Relevance: 100%
- Eli Lilly and Company's oncology drug, Jaypirca, has received expanded FDA approval for earlier use in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval allows the drug to be prescribed immediately after a covalent BTK inhibitor, converting its previous accelerated approval into a full traditional one based on phase 3 clinical study results. Despite a slight dip in stock price amidst broader market conditions, LLY continues to demonstrate strong long-term performance, reinforcing its position in cancer drug development.

**4. Eli Lilly and Company: Making Healthcare Accessible For All**
- Source: Sustainability Magazine | 20251205T133237 | Bullish | Relevance: 100%
- Eli Lilly and Company is committed to making healthcare more accessible globally through improved health literacy, sustainability initiatives, and affordable pricing strategies. The company aims for carbon neutrality by 2030, 100% renewable energy use, and zero waste to landfills from routine operations. They also focus on providing affordability solutions for patients and advocating for policy changes to reduce out-of-pocket costs and increase transparency in the US healthcare system.

**5. XLV ETF Rises to $155.29 as LLY Stock, JNJ, and ABBV Drive Healthcare Sector Gains**
- Source: TradingNEWS | 20251204T050942 | Bullish | Relevance: 93%
- The Health Care Select Sector SPDR Fund (XLV) has risen to $155.29, supported by its top holdings: Eli Lilly, Johnson & Johnson, and AbbVie. Eli Lilly's GLP-1 drugs and the stability provided by J&J and AbbVie's products are driving performance, making XLV a defensive yet growth-oriented investment for 2026. The ETF is rated a "Buy" with price targets between $165 and $172 for 2026, benefiting from low costs, strong dividends, and mega-cap leadership.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 11, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |
| 2025-11-19 | Truist Securiti | $1182 | $1038 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |
| 2025-11-19 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $18559M sold (28 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +16%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 31.0x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (11 raises, avg +16%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $966.2B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 31.0 |
| Current P/E | 42.7 |
| YoY Growth | 37.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to -4.5% (-7.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-13.00), momentum weakening. RSI neutral at 54. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.47% (CS: 14) | Weak |
| RSI_14 | 54.0 | Neutral |
| MACD Histogram | -13.00 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.244x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1010.31
- **Stop Loss:** $953.73 (5.6% risk)
- **Target:** $1123.47 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 8
- **Position Value:** $8,082.48
- **Portfolio %:** 8.08%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*